AZD0305

DRUG2 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Multiple MyelomaRelapsed or Refractory Multiple Myeloma

Phase 1

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

RecruitingNCT06106945

AstraZenecaMultiple Myeloma

Start: 2023-12-05End: 2027-08-16Target: 226Updated: 2026-08-19

A Modular Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy and in Combination With Anticancer Agent(s) in Participants with Relapsed or Refractory Multiple Myeloma

RecruitingCTIS2023-508590-89-00

AstraZeneca ABRelapsed or Refractory Multiple Myeloma

Start: 2024-06-25Target: 32Updated: 2025-12-29

Related Papers

A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood2024-11-055 citations